A patient died last week from a massive brain hemorrhage after mixing daily aspirin with fish oil supplements, all while following an influencer's advice without telling or consulting his cardiologist ...

The U.S. government struck drug pricing deals with nine leading drugmakers on Friday, with the most notable among them being Bristol Myers Squibb (BMY), which agreed to offer its blockbuster blood ...

A metallic taste during intense runs often signals fragile lung capillaries leaking blood due to increased blood pressure. While common after hard efforts, frequent occurrences may indicate ...

It appears that something very strange happened on the set of “Wicked 2.” Stars Cynthia Erivo and Ariana Grande have shrunken to a very small size at the same time. It’s a concerning example for girls ...

Q: After getting a pacemaker, my 90-year-old mother was diagnosed with A-fib. She resisted taking a blood thinner for stroke risk but finally agreed. Not 90 minutes after the first pill, she had a ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

BERLIN, Nov 23 (Reuters) - German pharma company Bayer (BAYGn.DE), opens new tab reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the ...

Texas Attorney General Ken Paxton speaks at the Austin Police Association in Austin, Texas, in September 2020. (Jay Janner/Austin American-Statesman via AP) MARSHALL, Texas (CN) — The makers of the ...

Shares of Bristol Myers Squibb (BMY) fell ~5% in the premarket on Friday after the company said that a Phase 3 trial for milvexian, an anticoagulant it is advancing with Johnson & Johnson (JNJ), is ...

The Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., September 23, 2025. REUTERS/Antranik Tavitian (This is an excerpt of the Health Rounds newsletter, ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.